References
- Zenz T, Mertens D, Döhner H, et al. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011;25:131–137.
- Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination? Am Soc Clin Oncol Educ Book. 2016;35:e387–e398.
- te Raa GD, Malcikova J, Pospisilova S, et al. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1849–1853.
- Kafkova LR, Navrkalova V, Jarosova M, et al. Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway. Leuk Lymphoma. 2017;58:199–203.
- Sanhes L, Tang R, Delmer A, et al. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. Leukemia. 2003;17:1104–1111.
- Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2015;29:1004–1017.
- Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Canc Metastasis Rev. 2012;31:75–87.
- Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;pii:30019–30015.